VIDEO: Expert highlights findings from the AVID200 study

In this video, Aaron T. Gerds, MD, MS, reviews data from the AVID200 study that was presented at ASH Annual Meeting and Exposition.

AVID200, a phase 1b study, enrolled patients with high-risk myelofibrosis who had intolerance or resistance to ruxolitinib (Opzelura, Incyte) and treated them with a TGF-beta 1/3 protein trap.

“The key piece going forward with this data will be understanding how stopping TGF beta in the patients it helped, what was the rational vs. the those who did not, so we can better tailor these therapies for this disease,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.

Reference

Mascarenhas J, et al. Abstract 142. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.

Take Homes in Myeloproliferative Neoplasms

Read more

VIDEO: Expert highlights findings from the AVID200 study

Reference

Related Content